Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI
Recent data suggest that the intracoronary (IC) administration of a systemic bolus dose of abciximab during PCI may increase the efficacy of this antiplatelet drug. However, the effect of IC abciximab on coronary angiographic flow has been not clarified. We studied 37 consecutive patients with acute...
Gespeichert in:
| Veröffentlicht in: | International journal of cardiology 2005-12, Vol.105 (3), p.250-255 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 255 |
|---|---|
| container_issue | 3 |
| container_start_page | 250 |
| container_title | International journal of cardiology |
| container_volume | 105 |
| creator | Romagnoli, Enrico Burzotta, Francesco Trani, Carlo Mazzari, Mario A. Biondi-Zoccai, Giuseppe G.L. De Vita, Maria Giannico, Floriana Niccoli, Giampaolo Prati, Francesco Rebuzzi, Antonio G. Mongiardo, Rocco Crea, Filippo |
| description | Recent data suggest that the intracoronary (IC) administration of a systemic bolus dose of abciximab during PCI may increase the efficacy of this antiplatelet drug. However, the effect of IC abciximab on coronary angiographic flow has been not clarified.
We studied 37 consecutive patients with acute coronary syndromes (ACS) who underwent successful urgent PCI on the target vessel and were treated by an IC abciximab bolus (0.25 mg/kg) prior to the first balloon inflation (Group IC), and 37 matched controls who were treated by intravenous (IV) abciximab bolus at the same dose (Group IV). Corrected TIMI frame count (CTFC) in the culprit and in a non-culprit coronary artery branch was assessed before treatment, immediately after intracoronary administration of abciximab bolus and at the end of the procedure.
After administration of abciximab, CTFC significantly decreased from 48
+
37 to 33
+
30 (
P
=
0.001) in the culprit vessel while in the non-culprit vessel it remained unchanged (16
+
7 pre-treatment and 16
+
7 post-treatment,
P
=
0.68). Final CTFC was 12
+
4 in Group IC and 14
+
5 in Group IV (
P
=
0.069). Post-treatment mean peak of the cardiac enzymes showed a trend toward reduction in Group IC compared with Group IV.
The IC administration of abciximab bolus acutely decreases CTFC through culprit vessels of patients with ACS undergoing urgent PCI. Further studies evaluating the potential clinical benefits associated with IC abciximab administration are warranted. |
| doi_str_mv | 10.1016/j.ijcard.2004.11.037 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68776679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527305002706</els_id><sourcerecordid>68776679</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-c34f40fa2196ce65a69ff1e4271282c27a0f937133587aae9f16e9b38820d5d33</originalsourceid><addsrcrecordid>eNp9kE1vEzEQhi0EomnhHyDkC9yy-GPXXl-QqghKpUpwgLM18Y63jjZ2au9W7b_HIZF64-Kxx887sh9CPnDWcMbVl10Tdg7y0AjG2obzhkn9iqx4r9s11137mqwqpted0PKCXJayYxU0pn9LLrgSutWqXZGH6ziGNGY43AdH8RGmBeaQIk2ezvdI0Xt08_EU4pzBpZwi5GcKWxeewh62FIZ9iKHUy3-5EOmh7jDOhS5xwDymEEe65LG26K_N7TvyxsNU8P25XpE_37_93vxY3_28ud1c362dNGyua-tb5kFwoxyqDpTxnmMrNBe9cEID80ZqLmXXawA0nis0W9n3gg3dIOUV-Xyae8jpYcEy230oDqcJIqalWNVrrZQ2FWxPoMuplIzeHnL9WX62nNmjaruzJ9X2qNpybqvqGvt4nr9s9zi8hM5uK_DpDEBxMPkM0YXywmmhmWRd5b6eOKw2HgNmW1z153AIubq3Qwr_f8lf9Guf-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68776679</pqid></control><display><type>article</type><title>Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Romagnoli, Enrico ; Burzotta, Francesco ; Trani, Carlo ; Mazzari, Mario A. ; Biondi-Zoccai, Giuseppe G.L. ; De Vita, Maria ; Giannico, Floriana ; Niccoli, Giampaolo ; Prati, Francesco ; Rebuzzi, Antonio G. ; Mongiardo, Rocco ; Crea, Filippo</creator><creatorcontrib>Romagnoli, Enrico ; Burzotta, Francesco ; Trani, Carlo ; Mazzari, Mario A. ; Biondi-Zoccai, Giuseppe G.L. ; De Vita, Maria ; Giannico, Floriana ; Niccoli, Giampaolo ; Prati, Francesco ; Rebuzzi, Antonio G. ; Mongiardo, Rocco ; Crea, Filippo</creatorcontrib><description>Recent data suggest that the intracoronary (IC) administration of a systemic bolus dose of abciximab during PCI may increase the efficacy of this antiplatelet drug. However, the effect of IC abciximab on coronary angiographic flow has been not clarified.
We studied 37 consecutive patients with acute coronary syndromes (ACS) who underwent successful urgent PCI on the target vessel and were treated by an IC abciximab bolus (0.25 mg/kg) prior to the first balloon inflation (Group IC), and 37 matched controls who were treated by intravenous (IV) abciximab bolus at the same dose (Group IV). Corrected TIMI frame count (CTFC) in the culprit and in a non-culprit coronary artery branch was assessed before treatment, immediately after intracoronary administration of abciximab bolus and at the end of the procedure.
After administration of abciximab, CTFC significantly decreased from 48
+
37 to 33
+
30 (
P
=
0.001) in the culprit vessel while in the non-culprit vessel it remained unchanged (16
+
7 pre-treatment and 16
+
7 post-treatment,
P
=
0.68). Final CTFC was 12
+
4 in Group IC and 14
+
5 in Group IV (
P
=
0.069). Post-treatment mean peak of the cardiac enzymes showed a trend toward reduction in Group IC compared with Group IV.
The IC administration of abciximab bolus acutely decreases CTFC through culprit vessels of patients with ACS undergoing urgent PCI. Further studies evaluating the potential clinical benefits associated with IC abciximab administration are warranted.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2004.11.037</identifier><identifier>PMID: 16274764</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Abciximab ; Acute coronary syndromes ; Angina, Unstable - therapy ; Angioplasty, Balloon, Coronary ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - pharmacology ; Anticoagulants - administration & dosage ; Anticoagulants - pharmacology ; Biological and medical sciences ; Cardiology. Vascular system ; Coronary Angiography - drug effects ; Coronary heart disease ; Emergency Treatment ; Female ; Heart ; Humans ; Immunoglobulin Fab Fragments - administration & dosage ; Immunoglobulin Fab Fragments - pharmacology ; Injections, Intra-Arterial ; Male ; Medical sciences ; Middle Aged ; Myocardial Infarction - therapy ; Percutaneous coronary interventions ; Prospective Studies</subject><ispartof>International journal of cardiology, 2005-12, Vol.105 (3), p.250-255</ispartof><rights>2005 Elsevier Ireland Ltd</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-c34f40fa2196ce65a69ff1e4271282c27a0f937133587aae9f16e9b38820d5d33</citedby><cites>FETCH-LOGICAL-c390t-c34f40fa2196ce65a69ff1e4271282c27a0f937133587aae9f16e9b38820d5d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijcard.2004.11.037$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17270305$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16274764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romagnoli, Enrico</creatorcontrib><creatorcontrib>Burzotta, Francesco</creatorcontrib><creatorcontrib>Trani, Carlo</creatorcontrib><creatorcontrib>Mazzari, Mario A.</creatorcontrib><creatorcontrib>Biondi-Zoccai, Giuseppe G.L.</creatorcontrib><creatorcontrib>De Vita, Maria</creatorcontrib><creatorcontrib>Giannico, Floriana</creatorcontrib><creatorcontrib>Niccoli, Giampaolo</creatorcontrib><creatorcontrib>Prati, Francesco</creatorcontrib><creatorcontrib>Rebuzzi, Antonio G.</creatorcontrib><creatorcontrib>Mongiardo, Rocco</creatorcontrib><creatorcontrib>Crea, Filippo</creatorcontrib><title>Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Recent data suggest that the intracoronary (IC) administration of a systemic bolus dose of abciximab during PCI may increase the efficacy of this antiplatelet drug. However, the effect of IC abciximab on coronary angiographic flow has been not clarified.
We studied 37 consecutive patients with acute coronary syndromes (ACS) who underwent successful urgent PCI on the target vessel and were treated by an IC abciximab bolus (0.25 mg/kg) prior to the first balloon inflation (Group IC), and 37 matched controls who were treated by intravenous (IV) abciximab bolus at the same dose (Group IV). Corrected TIMI frame count (CTFC) in the culprit and in a non-culprit coronary artery branch was assessed before treatment, immediately after intracoronary administration of abciximab bolus and at the end of the procedure.
After administration of abciximab, CTFC significantly decreased from 48
+
37 to 33
+
30 (
P
=
0.001) in the culprit vessel while in the non-culprit vessel it remained unchanged (16
+
7 pre-treatment and 16
+
7 post-treatment,
P
=
0.68). Final CTFC was 12
+
4 in Group IC and 14
+
5 in Group IV (
P
=
0.069). Post-treatment mean peak of the cardiac enzymes showed a trend toward reduction in Group IC compared with Group IV.
The IC administration of abciximab bolus acutely decreases CTFC through culprit vessels of patients with ACS undergoing urgent PCI. Further studies evaluating the potential clinical benefits associated with IC abciximab administration are warranted.</description><subject>Abciximab</subject><subject>Acute coronary syndromes</subject><subject>Angina, Unstable - therapy</subject><subject>Angioplasty, Balloon, Coronary</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Coronary Angiography - drug effects</subject><subject>Coronary heart disease</subject><subject>Emergency Treatment</subject><subject>Female</subject><subject>Heart</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - administration & dosage</subject><subject>Immunoglobulin Fab Fragments - pharmacology</subject><subject>Injections, Intra-Arterial</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - therapy</subject><subject>Percutaneous coronary interventions</subject><subject>Prospective Studies</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1vEzEQhi0EomnhHyDkC9yy-GPXXl-QqghKpUpwgLM18Y63jjZ2au9W7b_HIZF64-Kxx887sh9CPnDWcMbVl10Tdg7y0AjG2obzhkn9iqx4r9s11137mqwqpted0PKCXJayYxU0pn9LLrgSutWqXZGH6ziGNGY43AdH8RGmBeaQIk2ezvdI0Xt08_EU4pzBpZwi5GcKWxeewh62FIZ9iKHUy3-5EOmh7jDOhS5xwDymEEe65LG26K_N7TvyxsNU8P25XpE_37_93vxY3_28ud1c362dNGyua-tb5kFwoxyqDpTxnmMrNBe9cEID80ZqLmXXawA0nis0W9n3gg3dIOUV-Xyae8jpYcEy230oDqcJIqalWNVrrZQ2FWxPoMuplIzeHnL9WX62nNmjaruzJ9X2qNpybqvqGvt4nr9s9zi8hM5uK_DpDEBxMPkM0YXywmmhmWRd5b6eOKw2HgNmW1z153AIubq3Qwr_f8lf9Guf-Q</recordid><startdate>20051207</startdate><enddate>20051207</enddate><creator>Romagnoli, Enrico</creator><creator>Burzotta, Francesco</creator><creator>Trani, Carlo</creator><creator>Mazzari, Mario A.</creator><creator>Biondi-Zoccai, Giuseppe G.L.</creator><creator>De Vita, Maria</creator><creator>Giannico, Floriana</creator><creator>Niccoli, Giampaolo</creator><creator>Prati, Francesco</creator><creator>Rebuzzi, Antonio G.</creator><creator>Mongiardo, Rocco</creator><creator>Crea, Filippo</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051207</creationdate><title>Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI</title><author>Romagnoli, Enrico ; Burzotta, Francesco ; Trani, Carlo ; Mazzari, Mario A. ; Biondi-Zoccai, Giuseppe G.L. ; De Vita, Maria ; Giannico, Floriana ; Niccoli, Giampaolo ; Prati, Francesco ; Rebuzzi, Antonio G. ; Mongiardo, Rocco ; Crea, Filippo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-c34f40fa2196ce65a69ff1e4271282c27a0f937133587aae9f16e9b38820d5d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Abciximab</topic><topic>Acute coronary syndromes</topic><topic>Angina, Unstable - therapy</topic><topic>Angioplasty, Balloon, Coronary</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Coronary Angiography - drug effects</topic><topic>Coronary heart disease</topic><topic>Emergency Treatment</topic><topic>Female</topic><topic>Heart</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - administration & dosage</topic><topic>Immunoglobulin Fab Fragments - pharmacology</topic><topic>Injections, Intra-Arterial</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - therapy</topic><topic>Percutaneous coronary interventions</topic><topic>Prospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romagnoli, Enrico</creatorcontrib><creatorcontrib>Burzotta, Francesco</creatorcontrib><creatorcontrib>Trani, Carlo</creatorcontrib><creatorcontrib>Mazzari, Mario A.</creatorcontrib><creatorcontrib>Biondi-Zoccai, Giuseppe G.L.</creatorcontrib><creatorcontrib>De Vita, Maria</creatorcontrib><creatorcontrib>Giannico, Floriana</creatorcontrib><creatorcontrib>Niccoli, Giampaolo</creatorcontrib><creatorcontrib>Prati, Francesco</creatorcontrib><creatorcontrib>Rebuzzi, Antonio G.</creatorcontrib><creatorcontrib>Mongiardo, Rocco</creatorcontrib><creatorcontrib>Crea, Filippo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romagnoli, Enrico</au><au>Burzotta, Francesco</au><au>Trani, Carlo</au><au>Mazzari, Mario A.</au><au>Biondi-Zoccai, Giuseppe G.L.</au><au>De Vita, Maria</au><au>Giannico, Floriana</au><au>Niccoli, Giampaolo</au><au>Prati, Francesco</au><au>Rebuzzi, Antonio G.</au><au>Mongiardo, Rocco</au><au>Crea, Filippo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2005-12-07</date><risdate>2005</risdate><volume>105</volume><issue>3</issue><spage>250</spage><epage>255</epage><pages>250-255</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>Recent data suggest that the intracoronary (IC) administration of a systemic bolus dose of abciximab during PCI may increase the efficacy of this antiplatelet drug. However, the effect of IC abciximab on coronary angiographic flow has been not clarified.
We studied 37 consecutive patients with acute coronary syndromes (ACS) who underwent successful urgent PCI on the target vessel and were treated by an IC abciximab bolus (0.25 mg/kg) prior to the first balloon inflation (Group IC), and 37 matched controls who were treated by intravenous (IV) abciximab bolus at the same dose (Group IV). Corrected TIMI frame count (CTFC) in the culprit and in a non-culprit coronary artery branch was assessed before treatment, immediately after intracoronary administration of abciximab bolus and at the end of the procedure.
After administration of abciximab, CTFC significantly decreased from 48
+
37 to 33
+
30 (
P
=
0.001) in the culprit vessel while in the non-culprit vessel it remained unchanged (16
+
7 pre-treatment and 16
+
7 post-treatment,
P
=
0.68). Final CTFC was 12
+
4 in Group IC and 14
+
5 in Group IV (
P
=
0.069). Post-treatment mean peak of the cardiac enzymes showed a trend toward reduction in Group IC compared with Group IV.
The IC administration of abciximab bolus acutely decreases CTFC through culprit vessels of patients with ACS undergoing urgent PCI. Further studies evaluating the potential clinical benefits associated with IC abciximab administration are warranted.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>16274764</pmid><doi>10.1016/j.ijcard.2004.11.037</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2005-12, Vol.105 (3), p.250-255 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68776679 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Abciximab Acute coronary syndromes Angina, Unstable - therapy Angioplasty, Balloon, Coronary Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - pharmacology Anticoagulants - administration & dosage Anticoagulants - pharmacology Biological and medical sciences Cardiology. Vascular system Coronary Angiography - drug effects Coronary heart disease Emergency Treatment Female Heart Humans Immunoglobulin Fab Fragments - administration & dosage Immunoglobulin Fab Fragments - pharmacology Injections, Intra-Arterial Male Medical sciences Middle Aged Myocardial Infarction - therapy Percutaneous coronary interventions Prospective Studies |
| title | Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T10%3A37%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiographic%20evaluation%20of%20the%20effect%20of%20intracoronary%20abciximab%20administration%20in%20patients%20undergoing%20urgent%20PCI&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Romagnoli,%20Enrico&rft.date=2005-12-07&rft.volume=105&rft.issue=3&rft.spage=250&rft.epage=255&rft.pages=250-255&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2004.11.037&rft_dat=%3Cproquest_cross%3E68776679%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68776679&rft_id=info:pmid/16274764&rft_els_id=S0167527305002706&rfr_iscdi=true |